[go: up one dir, main page]

MX9702170A - Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres. - Google Patents

Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.

Info

Publication number
MX9702170A
MX9702170A MX9702170A MX9702170A MX9702170A MX 9702170 A MX9702170 A MX 9702170A MX 9702170 A MX9702170 A MX 9702170A MX 9702170 A MX9702170 A MX 9702170A MX 9702170 A MX9702170 A MX 9702170A
Authority
MX
Mexico
Prior art keywords
drug
aromatase inhibitors
men
preparation
treating
Prior art date
Application number
MX9702170A
Other languages
English (en)
Inventor
Albert Radlmaier
Ursula-Friederike Habenicht
Fierdmund Neumann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6529877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9702170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of MX9702170A publication Critical patent/MX9702170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invencion se relaciona con el uso de inhibidores de la aromatasa en la preparacion de un fármaco para tratar una deficiencia de androgeno relativa en los hombres. Los inhibidores de la aromatasa selectivos, tales como por ejemplo atamestano. formestano, pentrozol, arimidex, fadrozol, CGS 20267 y/o vorozol, se utilizan de preferencia para preparar el fármaco de acuerdo con la invencion.
MX9702170A 1994-09-22 1995-09-22 Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres. MX9702170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4435368A DE4435368A1 (de) 1994-09-22 1994-09-22 Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
PCT/EP1995/003733 WO1996009057A1 (de) 1994-09-22 1995-09-22 Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann

Publications (1)

Publication Number Publication Date
MX9702170A true MX9702170A (es) 1998-04-30

Family

ID=6529877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702170A MX9702170A (es) 1994-09-22 1995-09-22 Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.

Country Status (21)

Country Link
US (1) US5861389A (es)
EP (1) EP0782450B1 (es)
JP (1) JPH10505848A (es)
KR (1) KR100387345B1 (es)
CN (1) CN1104243C (es)
AT (1) ATE241989T1 (es)
AU (1) AU707997B2 (es)
BR (1) BR9509155A (es)
CA (1) CA2200195C (es)
CZ (1) CZ76097A3 (es)
DE (2) DE4435368A1 (es)
DK (1) DK0782450T3 (es)
ES (1) ES2199255T3 (es)
FI (1) FI971207A7 (es)
HU (1) HUT76981A (es)
MX (1) MX9702170A (es)
NO (1) NO971349L (es)
PL (1) PL182909B1 (es)
PT (1) PT782450E (es)
SK (1) SK36397A3 (es)
WO (1) WO1996009057A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610645A1 (de) * 1996-03-06 1997-09-11 Schering Ag Kombination von Dehydroepiandrosteron und Aromatasehemmern und Verwendung dieser Kombination zur Herstellung eines Arzeimittels zur Behandlung eines relativen und absoluten Androgenmangels beim Mann
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
AU2001261684B2 (en) 2000-05-26 2006-01-12 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US6607755B2 (en) 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
ATE406153T1 (de) * 2001-07-09 2008-09-15 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
HRP20040588A2 (en) * 2001-12-06 2004-10-31 Gtx Inc Treating muscle wasting with selective androgen receptor modulators
US6586417B1 (en) 2002-04-22 2003-07-01 Nutrisport Pharmacal, Inc. Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans
WO2004064814A1 (en) * 2003-01-13 2004-08-05 Michael Donald Farley Improvements in or relating to anti-aromatase composition
AU2003203010A1 (en) * 2003-01-13 2004-08-13 Michael Donald Farley Improvements in or relating to anti-aromatase composition
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP1776098A1 (en) * 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
EP1848416A4 (en) * 2005-02-04 2008-09-24 Repros Therapeutics Inc METHOD AND MATERIALS USING TRANS-CLOMIPHES FOR TREATING MALE INACCURIBILITY
CA3071412A1 (en) * 2005-03-22 2006-09-28 Allergan Pharmaceuticals International Limited Dosing regimes for trans-clomiphene
JP5123935B2 (ja) 2006-05-22 2013-01-23 ホルモス メディカル リミテッド 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法
JP5558358B2 (ja) 2007-10-16 2014-07-23 レプロス セラピューティクス インコーポレイティド メタボリック症候群用のｔｒａｎｓ−クロミフェン
WO2009066712A1 (ja) * 2007-11-21 2009-05-28 Kracie Pharma, Ltd. アロマターゼ阻害剤
US20090215738A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake
US20090306031A1 (en) * 2009-08-07 2009-12-10 Kneller Bruce W 5alpha-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR
WO2011016814A1 (en) * 2009-08-07 2011-02-10 Kneller Bruce W 5α-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CA2881604C (en) * 2011-08-09 2021-09-14 Kenneth W. Adams Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
DK2753312T3 (da) * 2011-09-08 2017-02-13 Mereo Biopharma 2 Ltd Anvendelse af en aromatase-inhibitor i behandlingen af hypogonadisme og relaterede sygdomme
CN102641502A (zh) * 2012-04-25 2012-08-22 中国农业大学 芳香酶抑制剂的新用途
MX2015005160A (es) 2012-11-02 2015-07-17 Repros Therapeutics Inc Trans-clomifeno para uso en terapia de cancer.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289762A (en) * 1980-06-27 1981-09-15 Merrell Dow Pharmaceuticals Inc. 10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors
US4322416A (en) * 1980-06-27 1982-03-30 Merrell Dow Pharmaceuticals Inc. 10-Alkynyl steroids
EP0100566B1 (en) * 1982-07-14 1986-02-19 Akzo N.V. Novel 19-thio-androstane derivatives
DE3322285A1 (de) * 1983-06-18 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3539244A1 (de) * 1985-11-01 1987-05-07 Schering Ag 1-methyl-15(alpha)-alkyl-androsta- 1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
GB8531745D0 (en) * 1985-12-24 1986-02-05 Erba Farmitalia 10beta-alkynyl-4-9(11)-estradiene derivatives
GB8615092D0 (en) * 1986-06-20 1986-07-23 Erba Farmitalia Androst-4-ene-317-diones
DE3705990A1 (de) * 1987-02-20 1988-09-01 Schering Ag 1-methyl-15(alpha)-(1-oxyalkyl)-androsta-1,4-dien- 3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3926365A1 (de) * 1989-08-04 1991-02-07 Schering Ag Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln
GB9226620D0 (en) * 1992-12-21 1993-02-17 Fujisawa Pharmaceutical Co A new compound fr 901537,production thereof and use thereof

Also Published As

Publication number Publication date
CN1158570A (zh) 1997-09-03
DE59510714D1 (de) 2003-07-10
ES2199255T3 (es) 2004-02-16
FI971207L (fi) 1997-03-21
NO971349L (no) 1997-05-16
CN1104243C (zh) 2003-04-02
FI971207A0 (fi) 1997-03-21
EP0782450B1 (de) 2003-06-04
EP0782450A1 (de) 1997-07-09
CZ76097A3 (en) 1997-07-16
KR100387345B1 (ko) 2003-08-30
CA2200195A1 (en) 1996-03-28
AU3651895A (en) 1996-04-09
CA2200195C (en) 2008-04-22
PT782450E (pt) 2003-09-30
FI971207A7 (fi) 1997-03-21
DK0782450T3 (da) 2003-08-18
NO971349D0 (no) 1997-03-21
ATE241989T1 (de) 2003-06-15
HUT76981A (hu) 1998-01-28
SK36397A3 (en) 1997-08-06
AU707997B2 (en) 1999-07-29
DE4435368A1 (de) 1996-03-28
PL182909B1 (pl) 2002-04-30
BR9509155A (pt) 1997-10-14
WO1996009057A1 (de) 1996-03-28
PL319299A1 (en) 1997-08-04
KR970706002A (ko) 1997-11-03
US5861389A (en) 1999-01-19
JPH10505848A (ja) 1998-06-09

Similar Documents

Publication Publication Date Title
MX9702170A (es) Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
BR9707233A (pt) Fenantridinas
ATE289191T1 (de) Verringerung der haarschädigung bei oxidativen prozessen
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE228502T1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
BR0107943A (pt) Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
DE69812159D1 (de) Derivate des adamantan
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
DK0889886T3 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
DK0934065T3 (da) Hidtil ukendte cruptophycinderivater som antieoplastiske midler
BR9913533A (pt) Processos para tratar hipertensão e composições para uso nos mesmos
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
ID24184A (id) Obat untuk perawatan disfungsi ereksi
BR9707844A (pt) Combinação de desidroepiandrosterona e inibidores de aromatase e emprego desta combinação para a preparação de um medicamento para o tratamento de uma deficiência de androgênio relativa e absoluta no homem
EA200401210A1 (ru) Андрогенная фармацевтическая композиция и способ для лечения депрессии
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
ES2059779T3 (es) Compuestos anti-androgenos.
BR0014145A (pt) Compostos de benzimidazol substituìdo por alcóxi, preparações farmacêuticas contendo o mesmo, e métodos de uso do mesmo
DK1189615T3 (da) Endoparasiticid synergistisk kombination indeholdende cykliske depsipeptider og piperaziner
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
NZ335015A (en) use of selective aromatase inhibitors for treating a relative androgen deficiency in men

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees